Edwards Lifesciences stock rises 5%, strong guidance offsets Q4 earnings miss

LootboxPhobia · 2026-02-13T22:52:50+00:00

Edwards Lifesciences stock rises 5% as optimistic guidance offsets slightly lower-than-expected Q4 results. The company's revenue increased year-over-year, mainly driven by TAVR and TMTT divisions. Revenue and earnings per share are expected to surpass market expectations in 2026, with an anticipated sales growth of 8-10%.

LootboxPhobia

2026-02-13 22:52:50

Abstract generation in progress

IRVINE, Calif. - Structural heart disease specialist Edwards Lifesciences (NYSE: EW) stock rose 5% after the company issued an optimistic outlook, offsetting the slightly below-expected fourth-quarter results.

The company reported adjusted earnings of $0.58 per share for the fourth quarter, below analysts’ expectations of $0.62, while revenue reached $1.57 billion, slightly above the market consensus of $1.55 billion. Revenue increased 13.3% year-over-year, and at constant currency, grew 11.6%.

Edwards’ largest business segment, transcatheter aortic valve replacement (TAVR), saw sales grow 12% to $1.16 billion, while its transcatheter mitral and tricuspid therapy (TMTT) segment achieved over 40% significant growth, reaching $156 million.

Investors responded positively to the company’s first-quarter 2026 guidance, expecting earnings of $0.70–0.76 per share, above the market consensus of $0.69, with revenue projected between $1.55 billion and $1.63 billion.

Edwards CEO Bernard Zovighian stated, “Edwards’ strong performance in Q4 and full year 2025 reflects our differentiated strategy, centered around three key elements: focusing on structural heart disease, addressing major, urgent, and highly complex patient needs, and pursuing unique opportunities for innovation and leadership.”

For the full year 2026, the company expressed “greater confidence” in achieving 8–10% sales growth and adjusted earnings of $2.90–$3.05 per share. The TMTT segment is expected to grow 35–45%, reaching $740–$780 million.

The company highlighted several growth catalysts for 2026, including long-term clinical trial results, the impact of the EARLY TAVR trial, new European guidelines for treating aortic stenosis, and the approval of the first transcatheter mitral valve replacement therapy.

By the end of 2025, Edwards had approximately $3 billion in cash and cash equivalents, with total debt of about $600 million.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.